Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Hypoxia on the Doxorubicin Sensitivity of Human MCF-7 Breast Cancer Cells

  • Lim, Soo-Jeong (Department of Bioscience and Biotechnology, Sejong University) ;
  • Kang, He-Kyung (Research Institute, National Cancer Center)
  • Published : 2007.10.21
Download PDF
⟨ Previous Next ⟩

Abstract

Intrinsic or acquired resistance to chemotherapeutic drugs is one of the major obstacles to effective cancer treatment. Hypoxia is widespread in solid tumors as a consequence of decreased blood flow in the tumor-derived neovasculature. The recent finding of a link between hypoxia and chemoresistance prompted us to investigate whether hypoxia induces doxorubicin resistance in human MCF-7 breast cancer cells. Low oxygen concentration decreased the doxorubicin sensitivity in MCF-7 cells. The expression of p-glycoprotein, a major MDR-related transporter, and those of apoptosis-related proteins (anti-apoptotic Bcl-2, Bcl-XL and pro-apoptotic Bax) were not altered by hypoxia in MCF-7 cells. Intracellular uptake of doxorubicin was significantly decreased under hypoxic conditions. Decreased cellular uptake of doxorubicin under hypoxia may contribute to causing doxorubicin resistance in these cells. The use of agents that can modulate the doxorubicin uptake for adjuvant therapy may contribute to improving the therapeutic efficacy of doxorubicin in breast cancer patients.

Keywords

References

  1. G.D. Leonard, T. Fojo and S.E. Bates. The role of ABC transporters in clinical practice. Oncologist, 8, 411-424 (2003) https://doi.org/10.1634/theoncologist.8-5-411
  2. P. Borst, R. Evers, M. Kool and J. Wijnholds. A family of drug transporters: the multi drug resistance-associated proteins. J. Natl. Cancer Inst., 92, 1295-1302 (2000) https://doi.org/10.1093/jnci/92.16.1295
  3. D. Hussein, E.J. Estlin, C. Dive and G. W. Makin. Chronic hypoxia promotes hypoxia-inducible factor-1 alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol. Cancer Ther., 5, 2241-2250 (2006) https://doi.org/10.1158/1535-7163.MCT-06-0145
  4. K. Sanna and E.K. Rofstad. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int. J. Cancer, 58, 258-262 (1994) https://doi.org/10.1002/ijc.2910580219
  5. Y. Shicang, H. Guijun, L. Yuying, W. Guoming and G. Ruiling. Efficacy of chemotherapeutic drugs under hypoxic conditions in pulmonary adenocarcinoma multidrug resistant cell line. J. Chemother., 19, 203-211 (2007) https://doi.org/10.1179/joc.2007.19.2.203
  6. M. Wartenberg, F.C. Ling, M. Mtischen, F. Klein, H. Acker, M. Gassmann, K. Petrat, V. Piltz, J. Hescheler and H. Sauer. Regulation of the multi drug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J., 17, 503505 (2003) https://doi.org/10.1096/fj.02-0358fje
  7. K.M. Comerford, T.J. Wallace, J. Karhausen, N.A. Louis, M.C. Montalto and S.P. Colgan. Hypoxia-inducible factor-ldependent regulation of the multidrug resistance (MDR 1) gene. Cancer Res., 62, 3387-3394 (2002)
  8. B.C. Liang. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J. Neurooncol., 29, 149-155 (1996)
  9. A. Jogi, J. Vallon-Christersson, L. Holmquist, H. Axelson, A. Borg and S. Pahlman. Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp. Cell Res., 295, 469-487 (2004) https://doi.org/10.1016/j.yexcr.2004.01.013
  10. C. Lotz, D.K. Kelleher, B. Gassner, M. Gekle, P. Vaupel and O. Thews. Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells. Oneal. Rep., 17, 239-244 (2007)
  11. A.E. Greijer, M.C. de Jong, G.L. Scheffer, A. Shvarts, P.J. van Diest and E. van der Wall. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol., 27, 43-49 (2005)
  12. V. Poulaki, C.S. Mitsiades and N. Mitsiades. The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist. Updat., 4, 233-242 (2005) https://doi.org/10.1054/drup.2001.0210
  13. H. Harada and S. Grant. Apoptosis regulators. Rev. Clin. Exp. Hematol., 7, 117-138 (2003)
  14. N. Raghunand, R. Hex van Sluis, B. Mahoney, B. Baggett, C.W. Taylor, G. Paine-Murrieta, D. Roe, Z.M. Bhujwalla and R.J. Gillies. Enhancement of chemotherapy by manipulation of tumour pH. Br. J. Cancer, 80, 1005-1011 (1999) https://doi.org/10.1038/sj.bjc.6690455
  15. C.C. Wykoff, NJ. Beasley, P.H. Watson, K.J. Turner, J. Pastorek, A. Sibtain, G.D. Wilson, H. Turley, K.L. Talks, P.H. Maxwel, C.W. Pugh, P.J. Ratcliffe and A.L. Harris. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res., 60, 7075-7083 (2000)